Submission of unaudited standalone and consolidated financial results for the quarter ended on 30.06.2026 as approved by The board of the directors in its meeting held on 06.08.2026

MEDI-CAPS LIMITED CIN: L70100MP1983PLC002231 MCL/SE/2026-2027 Date: 06.08.2026 Online filing at: www.listing.bseindia.com The General Manager DCS-CRD BSE Limited Phiroze Jeejeebhoy Towers, ‘A’ wing Dalal Street Fort, Mumbai — 400001 (M.H.) SUBJECT: OUTCOME OF BOARD MEETING HELD ON THURSDAY, 06™ AUGUST, 2026 PURSUANT TO REGULATION 30 OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015. REFERENCE: MEDI-CAPS LIMITED (BSE SCRIP CODE: 523144, ISIN: INE442D01010 Dear Sir/Madam, With reference to the above captioned subject and pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to inform that, Board of Directors at their meeting held on today ie. Thursday 06® August, 2026 has inter alia considered and approved the following :- (1) Un-audited Standalone and Consolidated Financial Results of the Company for the quarter ended on 30% June, 2026 along with Limited Review Report thereon. (Copy of financial results enclosed herewith). (2) Resignation of Mrs. Saloni Garg from the position of Senior Manager and Senior Management Personnel of the Company w.e.f. close of business hours on 06th August, 2026, in view of her appointment as Additional Director as well as Whole Time Woman Director of the Company. (3) Resignation of Mr. Akshit Garg from the position of General Manager and Senior Management Personnel of the Company w.e.f. close of business hours on 06th August, 2026, in view of his appointment as Chief Financial Officer (CFO) and Key Managerial Personnel (KMP) of the Company. (4) Based on recommendation of the Audit Committee and the Nomination and Remuneration Committee, approval for appointment of Mrs. Saloni Garg (DIN:11865402) as an “Additional Director as well as Whole Time Woman Director” of the Company for a period of three (3) years w.e.f 07" August, 2026, to 06™ August, 2029 subject to approval of the members of the Company at the ensuing 43rd Annual General Meeting. REGISTERED OFFICE 201, PUSHPRATNA PARADISE, 9/5 NEW PALASIYA INDORE - 452001 PH:- 0731-4028148, FAX:- 07314041435 E mail:- investors@medicaps.com, Web site:- www.medicaps.com MEDI-CAPS LIMITED CIN: L70100MP1983PLC002231 (5) Based on recommendation of the Nomination and Remuneration Committee, approval of re- appointment of Mr. Alok K. Garg (DIN: 00274321) Chairman cum Managing Director of the Company for a period of three years w.e.f. 01 September, 2026 to 31% August, 2029 subject to approval of the members of the Company at the ensuing 43 Annual General Meeting. (6) Based on recommendation of the Nomination and Remuneration Committee, approval for appointment of Mr. Akshit Garg as a Chief Financial Officer (CFO) and Key Managerial Personnel (KMP) oft he company w.e.f. 07.08.2026. (7) Approval of Board’s Report on the operations of the Company along with required annexure and Corporate Governance Report and Management Discussion and Analysis Report for the year ended 31st March, 2026. (8) Approval for convening of 43'¢ Annual General Meeting (AGM) on Tuesday, 22°¢ September, 2026 at 12.30 P.M. (IST) through Video Conferencing (VC) or Other Audio-Visual Means (OAVM). (9) Other routine businesses with the permission of Chair. Further, a copy of aforesaid Un-Audited Standalone and Consolidated Financial Results shall also be submitted in XBRL (Integrated Filing Financial) mode within prescribed time limit. The aforesaid Un-Audited Standalone and Consolidated Financial Results shall also be uploaded on the Company’s website www.medicaps.com and on the website of the Stock Exchange at www.bseindia.com. Further, publication containing a Quick Response code and the details of the webpage where complete financial results of the Company are available will be published in Hindi and English Newspapers within prescribed time limit. Further the requisite Continuous Disclosure’s as required pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Schedule IIT thereof and SEBI Master Circular No. HO/49/14/14(7)2025-CFD-PoD2/1/3762/2026 dated 30™ January, 2026 as amended from time to time, are being filed separately with respect to the businesses transacted at the meeting. The Meeting oft he Board of Directors commenced at 03:00 P.M. and concluded at 03.55 P.M. The above information will also be available on the website of the Company at www.medicaps.com. This is for your information and record. Thanking You, REGISTERED OFFICE 201, PUSHPRATNA PARADISE, 9/5 NEW PALASIYA INDORE - 452001 PH:- 0731-4028148, FAX:- 0731-4041435 E mail:- investors@medicaps.com, Web site:- www.medicaps.com MEDI-CAPS LIMITED CIN: L70100MP1983PLC002231 Yours Faithfully, FOR MEDI-CAPS LIMITED ALOK K GARG MANAGING DIRECTOR DIN: 00274321 Encl.: Un-audited Standalone and Consolidated Financial Results along with limited review report for quarter ended on 30" June, 2026. REGISTERED OFFICE 201, PUSHPRATNA PARADISE, 9/5 NEW PALASIYA INDORE - 452001 PH:- 0731-4028148, FAX:- 0731-4041435 E mail:- investors@medicaps.com, Web site:- www.medicaps.com RAWKA & ASSOCIATES -----------------------CHARTEREDACCOUNTANTS----- 412, Arcade Silver 56, 1, New Palasia, Indore -1 ~Off.: 2541132, Mobile: 9039080380 E-mail: rawkaassociates@gmail.com,. cprawka@gmail.com LIMITED REVIEW REPORT Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results for the quarter ended 30th June, 2026 of Medi-Caps Limited (the Company) Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended THE BOARD OF DIRECTORS OF MEDI-CAPS LIMITED INDORE (M.P.) SCOPE OF THE REVIEW 1. We have reviewed the accompanying statement of unaudited standalone financial results ("the Statement") of MEDI-CAPS LIMITED ("the Company") for the quarter ended 30th June 2026 attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended ('SEBI Listing Regulations'), including relevant circulars issued by the SEBI from time to time. 2. The Statement is the responsibility of the Company's Management and has been approved by the Company's Board of Directors. Our responsibility is to issue a report on the Statement based on our review of the Statement, which has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), specified under Section 133 of the Companies Act, 2013 read with relevant rules issued there under, and other accounting principles generally accepted in India and in Compliance with Regulation 33 of the SEBI Listing Regulations. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and · applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we -- - - - - - -- - - - -------~- - - - --- --- - - - - - would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. CONCLUSION 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in ac [Showing first 8,000 characters — download PDF for full document]